Endocannabinoid system for the treatment of paintreatment
Posted 28 April 2009 - 05:15 PM
The use of cannabis has been described in classical and recent literature for the treatment of pain, but the potential for psychotropic effects as a result of the activation of central CB(1) receptors places a limitation upon its use. There are, however, a number of modern approaches being undertaken to circumvent this problem, and this review represents a concise summary of these approaches, with a particular emphasis upon CB(2) receptor agonists.
Selective CB(2) agonists and peripherally restricted CB(1) or CB(1)/CB(2) dual agonists are being developed for the treatment of inflammatory and neuropathic pain, as they demonstrate efficacy in a range of pain models. CB(2) receptors were originally described as being restricted to cells of immune origin, but there is evidence for their expression in human primary sensory neurons, and increased levels of CB(2) receptors reported in human peripheral nerves have been seen after injury, particularly in painful neuromas.
CB(2) receptor agonists produce antinociceptive effects in models of inflammatory and nociceptive pain, and in some cases these effects involve activation of the opioid system. In addition, CB receptor agonists enhance the effect of mu-opioid receptor agonists in a variety of models of analgesia, and combinations of cannabinoids and opioids may produce synergistic effects. Antinociceptive effects of compounds blocking the metabolism of anandamide have been reported, particularly in models of inflammatory pain.
There is also evidence that such compounds increase the analgesic effect of non-steroidal anti-inflammatory drugs (NSAIDs), raising the possibility that a combination of suitable agents could, by reducing the NSAID dose needed, provide an efficacious treatment strategy, while minimizing the potential for NSAID-induced gastrointestinal and cardiovascular disturbances.
Other potential "partners" for endocannabinoid modulatory agents include alpha(2)-adrenoceptor modulators, peroxisome proliferator-activated receptor alpha agonists and TRPV1 antagonists. An extension of the polypharmacological approach is to combine the desired pharmacological properties of the treatment within a single molecule. Hopefully, these approaches will yield novel analgesics that do not produce the psychotropic effects that limit the medicinal use of cannabis.
Posted 28 March 2015 - 03:48 PM
that is old science...... good.... but old..... they have found more receptors in recent yearz !!!!!!!!!!!!!!
here is what we know now as we all start batting the sciences around
in order to move forward we need to be willing to let go of old science and be able to receive new info.
its hard to un-learn the learned, so be careful how you store your info in your mind
- skh, slab, mactheman and 3 others like this
i like to weez on the juice
Posted 28 March 2015 - 05:01 PM
It all starts with unlocking the handcuffs placed on researchers by the Man.
I firmly believe that one day, humanity will discover a cure for cancer hidden inside cannabis. And only then will the full scope of the propaganda and the wars and the laws and the prison sentences and all the other nonsense be known and the full tally of the cost be calculated.
Posted 28 March 2015 - 11:37 PM
I firmly believe that one day, humanity will discover a cure for cancer hidden inside cannabis
We already have Trout, it's old news. Part of the reason why weed is illegal most places. Big Pharma don't like competition and according to the PTB the world is overpopulated.
Posted 15 April 2015 - 03:22 PM
good morning guys.
here is some info you might find interesting..
- twistyman, EkimRI, GrooT'mag and 5 others like this
“There is no need to subject people to life-altering criminal penalties simply for using a substance that is objectively less harmful than alcohol.”
success comes to those that don't give up..
0 user(s) are reading this topic
0 members, 0 guests, 0 anonymous users